BSX · 10-Q · 2026Q2 · Full report

Operating Expense Trends

BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 49 · Surprise 32 · No source text

Second-quarter SG&A expense increased $87 million, or 5%, to $1.803 billion, while six-month SG&A increased $271 million, or 8%, to $3.583 billion. SG&A declined as a percentage of sales by 80 basis points to 33.1% in the quarter and by 40 basis points to 33.7% year to date, primarily because selling costs grew more slowly than revenue. Second-quarter R&D expense increased $28 million, or 5%, and six-month R&D increased $100 million, or 10%, to $1.069 billion. R&D investment supported product-development programs across the businesses and remained 10.2% of sales in the quarter and 10.0% year to date.

Key facts

• Selling, general and administrative (SG&A) expenses for the three months ended June 30, 2026 were $1,803 million, or 33.1% of net sales, versus $1,716 million, or 33.9% of net sales in the prior year period. source
• SG&A expenses increased $87 million, or 5%, in Q2 2026 compared to prior year and were 80 basis points lower as a percentage of net sales; the increase was primarily driven by selling expenses associated with higher net sales. source
• Research and development (R&D) expenses for the three months ended June 30, 2026 increased $28 million, or 5%, compared to the prior year period and were 20 basis points lower as a percentage of net sales. source

Impact estimates